Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir Digihaler (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the first findings from the CONNECT clinical program on ProAir Digihaler (albuterol sulfate) inhalation powder with an integrated electronic module (eModule) will be presented at the European Respiratory Society (ERS) International Congress 2022, held September 4-6
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir Digihaler (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the first findings from the CONNECT clinical program on ProAir Digihaler (albuterol sulfate) inhalation powder with an integrated electronic module (eModule) will be presented at the European Respiratory Society (ERS) International Congress 2022, held September 4-6